Hua Medicine (HKSE:02552) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02552 Hua Medicine HKSE:02552
46 GF Score
Price HK$2.51
GF Value HK$8.74
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Hua Medicine FFO?

FFO (Funds from operations) only applies to REITs.

HKSE:02552
46GF Score
Hua Medicine HKSE:02552
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Hua Medicine (HKSE:02552) Overvalued in 2026?

Based on GuruFocus' analysis, Hua Medicine stock appears to be undervalued. The current stock price of HK$2.51 is trading 71.3% below its estimated GF Value™ of HK$8.74. GuruFocus considers Hua Medicine to be Possible Value Trap.

Key valuation signals for HKSE:02552:

  • FFO:
  • GF Value™: HK$8.74 vs. price of HK$2.51 (71.3% below fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the HKSE:02552 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hua Medicine Business Description

Other Exchanges HUMDF:USA
Address Lane 36, Xuelin Road, Hua Medicine, Building 2, Pudong New Area, Shanghai, CHN, 201203
Hua Medicine is an investment holding company. It is engaged in the development and commercialization of a first-in-class oral drug, Dorzagliatin (HMS5552), for the treatment of Type 2 diabetes. Dorzagliatin is a first-in-class glucokinase activator, or GKA, designed to control the progressive degenerative nature of diabetes by restoring glucose homeostasis in Type 2 diabetes. The group majorly operates and generates the majority of its revenue from the PRC.
46GF Score

Get the complete analysis for HKSE:02552

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$2.51
Price
HK$8.74
GF Value